Scientists block stomach tumor growth

Stomach cancer is the second most lethal cancer in the world and is extremely aggressive. The discovery of the TLR2 gene's involvement in promoting tumour growth could lead to early detection options and potential new treatments. Credit: janulla/iStockphoto

(Medical Xpress)—Monash Institute of Medical Research scientists may have discovered a way of blocking stomach tumours from growing and spreading, according to a paper published in the highly-prestigious journal Cancer Cell.

Stomach, or gastric, cancer is the second most lethal cancer in the world, and being one of the most aggressive forms of cancer it is also placed among the world's top five cancers with the lowest .

In a world-first, MIMR's Associate Professor Brendan Jenkins and his team from the Centre for Innate Immunity and have identified that a gene, which creates a protein called Toll-Like Receptor 2, is over-produced in the stomachs of gastric cancer patients.

They have also identified why this happens.

Completing the trifecta, A/Prof Jenkins and his team have also demonstrated that TLR2 promotes the growth of gastric cancer tumour cells, and by using an antibody can block the actions of TLR2, thus preventing further tumour growth and potentially spreading (metastasis).

"One of the main problems with is that it's a very and is often only detected at an advanced stage where you are restricted to harsh treatments such as chemotherapy, radiotherapy and surgical resection," A/Prof Jenkins said

"These can have quite dire consequences in terms of the patient's quality of life, and often are not highly effective at preventing tumours from regrowing or significantly improving the survival rate of patients.

"So there's a very strong need for new next-generation therapeutics for gastric cancer to overcome these issues" he said.

A/Prof Jenkins' findings now create the potential for personalised .

They also highlight the need and pave the way for early detection.

"Using TLR2 and other related disease biomarkers we've identified could enhance screening programs to capture stomach cancer in its early stages and allow us to block further tumour growth before it has a major detrimental effect on peoples' lives," he said.

A/Prof Jenkins and his team collaborated with several international groups including Dublin-based pharmaceutical company Opsona, which provided the , as well as the Genome Institute of Singapore and Japan's Kanazawa University.

Despite his findings, A/Prof Jenkins is still very cautious about his research's blanket potential.

"If we prove antibody-mediated therapy against TLR2 is efficacious in our pre-clinical models, we still couldn't say that it can treat every gastric cancer patient – that's just unrealistic," he said.

"At this stage we don't know exactly what percentage of stomach/gastric cancer patients worldwide would have increased amounts of the TLR2 gene (and protein) and therefore, how many gastric would respond to or benefit from this.

"But you're looking at a percentage of advanced patients – around 20-30 per cent based on our numbers so far – that we believe would benefit.

"In five years from now I would like to see this treatment in the clinics with people receiving and benefiting from it, which means hopefully that it will provide them with an improved quality of life," A/Prof Jenkins said.

Cancer Council Victoria's CEO Todd Harper said the Cancer Council has been instrumental in funding A/Prof Jenkins' research.

"We're excited about the initial results of A/Professor Jenkins' work – particularly as it relates to a cancer which presently has such a low survival rate.

"Our priority is to fund life-saving cancer research so we're eager to see what developments will be made with these findings," Mr Harper said.

add to favorites email to friend print save as pdf

Related Stories

Study reveals optimal interval for stomach cancer screening

Jul 16, 2012

A new study has determined how often people should get screened for gastric or stomach cancer in high-risk regions of the world. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the fi ...

Merck KGaA suffers setback on cancer drug

Jul 05, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Primary driver of stomach cancer development identified

Apr 23, 2008

In a discovery that could lead to the development of new treatments for gastric cancer, scientists at the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have discovered what appears to be ...

Stomach bacterium damages human DNA

Sep 06, 2011

The stomach bacterium Helicobacter pylori is one of the biggest risk factors for the development of gastric cancer, the third most common cause of cancer-related deaths in the world. Molecular biologists from the University of Zur ...

Recommended for you

Bone loss drugs may help prevent endometrial cancer

7 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.